Zhenoluten is a Russian bioregulator peptide complex marketed for female reproductive health and ovarian function support. Developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology, it is derived from young animal ovarian tissue extracts. It is promoted for improving ovarian function, normalizing menstrual cycles, and supporting fertility in perimenopausal women. There is no peer-reviewed clinical evidence meeting international standards, and the product is not recognized by any Western regulatory agency.
Category: Bioregulator / Reproductive. Evidence rating: F (anecdotal/unsupported).
Clinical status: No clinical trials in international registries. Available as a dietary supplement in Russia.
Zhenoluten is claimed to contain ovary-specific short peptides that regulate gene expression in ovarian tissue, restoring youthful hormonal output and follicular function. According to the Khavinson bioregulation theory, these tissue-specific peptides interact directly with DNA to modulate…
Safety considerations: No formal safety assessment by any international regulatory agency; Derived from animal ovarian tissue; potential contamination with hormones or infectious agents; Effects on reproductive hormones are unpredictable and uncharacterized.
Reviewed by the PeptideAtlas Editorial Team.
| Production method | bioactive |
|---|---|
| Anti-doping status | not-listed |
| US regulatory status | Not FDA-approved. Not recognized as a therapeutic or supplement. |
There is no credible evidence that Zhenoluten improves fertility. Age-related decline in ovarian function is primarily due to depletion of the finite oocyte pool, which cannot be reversed by any known peptide therapy. Women seeking fertility support should consult a reproductive endocrinologist.
No. It is marketed as a bioregulator peptide complex, not as hormone therapy. However, since it is derived from ovarian tissue, it may contain trace hormonal contamination. Its actual hormonal effects are unknown.
There are no clinical trials registered in international databases (ClinicalTrials.gov, ISRCTN, etc.), no peer-reviewed publications in internationally recognized journals, and no independent replication of any claimed effects. The product is based on the Khavinson bioregulator theory, which is not accepted by mainstream medicine.